Bluepoint Laboratories

BORTEZOMIB

  1. Home
  2.  / 
  3. J Code
  4.  / BORTEZOMIB – J9041

Manufacturer:

Bluepoint Laboratories

Name:

BORTEZOMIB

HCPCS Code Descriptor:

Injection, bortezomib, 0.1 mg

Category:

J Code

HCPCS:

J9041

NDC(s):

72205-0183-01, 71288-0118-10, 70860-0225-10, 70710-1411-01, 68001-0540-36, 68001-0534-36, 63323-0821-10, 63020-0049-01, 60505-6050-04, 55150-0337-01, 50742-0484-01, 43598-0426-60, 25021-0244-10, 10019-0991-01, 00409-1700-01, 00143-9098-01

Primary Type:

Oncology

Generic Status:

Multi-Source

Route of Administration:

Injection

About:

BORTEZOMIB is an Oncology drug manufactured by Bluepoint Laboratories and administered via the Injection route of administration. The J Code: J9041 is aligned to the drug BORTEZOMIB.

Bortezomib is an anti-cancer drug which inhibits rapid cell growth. This drug is administered by a doctor or a healthcare professional via injection into a vein. Bortezomib is a generic drug that is produced by multiple manufacturers including Fresenius Kabi, Hospira, Bluepoint Laboratories, Baxter, and others. Fresenius Kabi (J9048) and Hospira (J9049) each have their own unique HCPCS for Bortezomib distinct from the generic HCPCS code (J9041).

Access Pricing and More By Registering

HCPCS Added Date:

1/1/05

HCPCS Effective Date:

1/1/23

HCPCS Short Description:

Injection, bortezomib, 0.1mg

Billing and Coding Guide:

Not Found

Patient Assistance:

https://www.velcade.com/support-from-takeda/

https://kabicare.us/patient/